It was an open-label trial which showed that hs-CRP levels were significantly decreased after four weeks in both rosuvastatin and atorvastatin groups (P < 0.001). Qian C, Wei B, Ding J, Wu H, Cai X, Li B, Wang Y. Optical coherence tomography and intravascular ultrasound were performed at baseline, 6 months, and 12 months. Further concerns about rosuvastatin’s renal effects were seen in an AstraZeneca funded randomized study comparing high dose rosuvastatin with atorvastatin in diabetic patients with progressive kidney disease.19 Although rosuvastatin lowered plasma lipid concentrations to a greater extent than atorvastatin, the study reported that “atorvastatin seems to have more renoprotective effects.” Urinary protein excretion was reduced during one year of treatment with atorvastatin … In a randomized open-label trial with diabetic patients, only atorvastatin significantly reduced hs-CRP levels (p=0.02) while rosuvastatin did not. Hs-CRP levels were less elevated in the rosuvastatin group than in the control group at 24 hours after PCI. Patients who were surgically managed were also excluded. In another randomized double-blind trial, there was a statistically significant reduction in hs-CRP levels with both atorvastatin and rosuvastatin. Randomized trials, as well as meta-analyses, have shown superior effects of rosuvastatin in reverting coronary atherosclerotic plaques and reduction of hs-CRP levels [10-11]. Statins impart pleiotropic effects - that is, they are simultaneously capable of producing more than one benefit, and in cardiovascular risk reduction, they accomplish more than simply lowering cholesterol on the vasculature which contributes to their anti-anginal and anti-ischemic traits. At baseline there were 104 patients in group A and 103 in group B. We aimed to investigate coronary plaque response to treatment with different statins that result in similar lipid reduction using serial multimodality intracoronary imaging. This study has evaluated that although the lipid-lowering effects of atorvastatin and rosuvastatin are comparable, the latter has a more profound impact on the reduction of pro-inflammatory markers, especially hs-CRP, which is an established predictor of cardiovascular morbidity and mortality. Scholary Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Effective medical intervention to control this underlying micro-inflammation has a critical role in preventing mortality and bettering disease outcome. Elevated hs-CRP has been established as a prognostic indicator of new MACE and mortality in patients with ACS . Variability in blood lipids affects the neutrophil to lymphocyte ratio in patients undergoing elective percutaneous coronary intervention: a retrospective study. In order to compare the effects of atorvastatin and rosuvastatin on the inflammatory markers in patients of ACS, we included adult patients of age 18 years and above, of both genders, diagnosed with STEMI, NSTEMI, or UA according to World Health Organization criteria  who were not taking statins. The literature regarding the superiority of either statin in the reduction of pro-inflammatory markers is not concrete. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature, Comparative effect of atorvastatin and rosuvastatin on 25-hydroxy-vitamin D levels in non-diabetic patients with dyslipidaemia: a prospective randomized open-label pilot study, 10.2174/187419240140801005510.2174/187419240140801005510.2174/187419240140801005510.2174/187419240140801005510.2174/187419240140801005510.2174/187419240140801005510.2174/1874192401408010055, Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (< 2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study), Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients, Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome, A comparative study on the effect of HMG-CoA reductase inhibitors on C-reactive protein in patients with acute coronary syndrome, 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome, Predictors of adverse outcome in patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease. Each email address must be separated by a comma. With four weeks of treatment, both rosuvastatin 40 mg group and atorvastatin 20 mg group showed a statistically significant reduction in ESR levels (p <0.05). Rosuvastatin showed a 50% decrease and atorvastatin showed a 35% reduction in serum hs-CRP levels in statin-naive ACS patients.